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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not etanercept
is a safe and effective treatment for ankylosing spondylitis (AS).
Study Design: Review of three English language randomized control trials published in 2007,
2008, and 2010.
Data Sources: Two double-blind placebo-controlled randomized controlled trials and one
placebo-controlled randomized control trial comparing etanercept to placebo were found using
PubMed.
Outcomes Measured: Work instability was measured through the Ankylosing Spondylitis Work
Instability Scale (AS-WIS) based on scores of 1-20. Quality of life was measured through the
EuroQOL-5D (EQ-5D), which assesses mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression. Physical functioning was evaluated through the Bath Ankylosing Spondylitis
Functioning Index (BASFI) where scores for functional limitation range from 1-100. Lastly, the
safety and tolerability of etanercept were assessed based on personal reports from the patients
themselves.
Results: In a study by Barkham et al, etanercept treatment was not found improve work
instabililty but not to the point of statistical significance. Risk of job loss was also decreased in
those who received etanercept treatment. Quality of life was considerably improved with
etanercept therapy as seen in a RCT by Braun et al. This study also illustrated statistically
significant improvement in physical functioning in those who obtained etanercept verse placebo.
Long-term treatment with etanercept for 192 weeks was shown to be safe and tolerable in a study
conducted by Davis et al. The most common adverse effect of etanercept therapy was injection
site reaction where more reactions were present compared with placebo.
Conclusions: The results of two of the randomized control trials demonstrate etanercept to be a
safe and effective treatment for ankylosing spondylitis. One randomized control trial does not
reach statistical significance.
Key Words: Ankylosing Spondylitis, Etanercept

INTRODUCTION
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Ankylosing spondylitis (AS), one of the spondyloarthropathies, is a type of inflammatory
arthritis that has an effect on the axial skeleton, and if severe, other parts of the body.
Inflammation of the spinal joints can cause chronic pain and possible spinal immobility due to
fusing of vertebrae over time.1 Ankylosing spondylitis affects men two to three times more than
women and greatly impacts one’s quality of life. There is no current cure for AS; however, many
drugs and therapies have been studied for symptom reduction, pain control and improvement of
quality of life.2 This paper assesses three randomized control trials evaluating the effectiveness
and safety of etanercept (Enbrel®) as a treatment for AS.
Although AS only affects 0.25% of the population, it is of importance to Physician
Assistant practice due to the impact the disease can have on a person’s life. Low back pain is
one of the most frequent reason for a visit to a primary care physician, and 5% of those
presenting with this pain have a spondyloarthropathy present.3 Low back pain is often the
presenting complaint of those with AS. Another frequent finding among those with AS is the
gene protein Human Leukocyte Antigen (HLA)-B27 which is seen in 7% of the US population.
This gene protein is present in 90% of persons with AS.2 Knowledge of this frequent finding
allows the Physician Assistant to be able to help reduce the patient’s chronic pain and systemic
effects, slow down eventual immobility, and improve quality of life. An average of $6,720 is
spent on each of the estimated 30,000 AS patients who visit their primary physicians each
year.4,5
The precise cause of AS is unknown, but genetics are thought to play a role with the gene
protein HLA-B27. Ankylosing spondylitis can be present without HLA-B27 due to a possible
immune-mediated reaction pathogenesis, because environmental factors or bacterial infections
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(especially gastrointestinal) can prompt AS in those inclined. Tumor necrosis factor (TNF)-α,

TH17 T cells, CD4+ and CD8+ T cells, macrophages, and abundant transforming growth factor
(TGF)-β are all thought to play a role in this immune-mediated reaction.2 Ankylosing spondylitis
usually presents around 20-30 years of age and begins with complaints of low back pain. Acute
painful flare-ups and remissions characterize AS, and involvement of bilateral sacroiliac joints is
a hallmark feature.6 A diagnosis of AS is based on many factors since there is no specific
diagnostic criteria for it. The patient may have pain upon palpation of the spine and sacroiliac
joints and a positive Schober test: stretching of the skin upon spinal flexion of less than 15 cm
between the sacral dimples and 10 cm above that.6 Anterior uveitis is the most common extraarticular manifestation of AS affecting 1/3 of the patients at least once.1 Other manifestations of
AS are peripheral arthritis, enthesitis around the pelvis and calcaneus, inflammatory bowel
disease, and decreased chest expansion.6
Treatment for AS should always begin with non-steroidal anti-inflammatory drugs
(NSAIDs). NSAIDs have been shown to improve range of motion and decrease pain, allowing
for better daily functioning.2 All patients with AS should be involved in a physical therapy
exercise program to help maintain posture and further improve mobility. Anti-TNF α therapy
such as infliximab, adalimumab, and golimumab has shown to have a positive impact on
symptom reduction and slowing disease progression and is another form of treatment commonly
used. Surgery is a last resort treatment for those not responding to any other form of therapy.
Common surgeries performed are total hip arthroplasties and spinal osteotomy with fixation.6
Symptom control has been the main aim for treatment through NSAIDs and exercise.
Etanercept (Enbrel), an anti-TNF α drug commonly used for treatment of rheumatoid arthritis,
has been revealed to both rapidly suppress disease activity and decrease symptoms in those with
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AS.7,8 Improving symptoms when other treatment options have failed can greatly increase one’s
quality of life.
OBJECTIVE

The objective of this systematic review is to determine whether or not etanercept is a safe
and effective treatment for ankylosing spondylitis. Previous randomized control trials have
determined etanercept as both a safe and effective treatment for ankylosing spondylitis.
METHODS
Specific selection criteria of three randomized control trials (RCT) were used for this
review. One of these RCTs was an open label extension (OLE). The population chosen was
patients (both men and women) > 18 years of age with ankylosing spondylitis. The interventions
utilized in each RCT were either etanercept 25mg subcutaneously twice per week7,9 or etanercept
50mg subcutaneously once per week8. Comparisons were made between 25mg or 50mg
etanercept to a placebo. Outcomes measured in each study were all based on patients oriented
evidence that matters (POEMs). One outcome is change in work instability which is defined as
“a state in which the consequences of a mismatch between an individual’s functional abilities
and the demands of his or her job can threaten continuing employment if not resolved”.7 Quality
of life including physical functioning, vitality, social functioning, mental health, physical and
emotional role limitations, bodily pain, general health, and fatigue was also assessed.8 Lastly,
safety associated with adverse events and tolerability of etanercept were measured.9
Key words used in the searches were “etanercept” and “ankylosing spondylitis”. All
articles search were published in peer-reviewed journals and in the English language. The author
researched the studies through PubMed and selected the articles based on POEMs. Inclusion
criteria consisted of studies that were randomized control trials published after 1996 with
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participants over the age of 18 years old. Exclusion criteria included articles with disease-

oriented evidence (DOE), published before 1996, or with participants under the age of 18 years
old. The statistics used in the studies were 95% confidence intervals (CI), ANCOVA, ANOVA,
Fisher’s exact test, and χ2 analyses all converted into p-values.
OUTCOMES MEASURED
Outcomes measured were based on scales or actual patient reports. Work instability was
measured through the Ankylosing Spondylitis Work Instability Scale (AS-WIS), which measures
the risk of job loss on a scale of 1-20. Low risk scores are those <11, medium risk ranges from
11-18, and high risk is 19-20.7 Quality of life was assessed by the EuroQOL-5D (EQ-5D) which
includes five aspects of health such as mobility, self care, usual activities, pain/discomfort, and
anxiety/depression.8 Included in quality of life is vitality, social functioning, mental health,
physical and emotional role limitations, bodily pain, general health, and fatigue. The Bath
Ankylosing Spondylitis Functional Index (BASFI) was used to measure physical functioning
based on 10 different daily functioning questions each with a Likert scale ranging from 1 (easy) 10 (impossible) on each question. The highest score possible is 100, which means the physical
functioning is severely impacted. Some questions included are “Bending from the waist to puck
up a pen from the floor without aid” and “standing unsupported for 10 minutes without
discomfort”.10 Safety and tolerability of etanercept were both measured based on actual reports
of patients participating in the study.
RESULTS
The three randomized control trials in this systematic review compared etanercept to
placebo. Two of the studies were 12-week experimentations (Barkham, Braun) and one was 192

Albert, Etanercept and Ankylosing Spondylitis 5

weeks (Davis). Patients in each study were allowed to continue on a steady dose of disease-

modifying antirheumatic drugs (DMARDs) and NSAIDs. DMARDs permitted in all three were
Table 1: Demographics and Characteristics of Included Studies
Study

Type

Barkham, RCT
20104

#
Pts
40

Age (yrs)
Placebo
mean39.4;
Etanercept
mean- 40.8

Braun,
20075

RCT

361

18-70

Davis,
20086

RCT
(OLE)

277

Mean- 41.6

Inclusion
Criteria
Patients
currently
working with
active AS,
but were
unstable at
work with an
AS-WIS >10
Patients with
active AS
and morning
stiffness >30
according to
the visual
analog scale
along with 2
of the
following:
VAS for
assessment
of disease
activity or
nocturnal and
total pain
>30; BASFI
>30
Patients with
active AS
previously
enrolled in a
RCT, who
chose to
continue on
with an
open-label
extension

Exclusion
W/D
Criteria
Past or current 0
tuberculosis,
congestive
heart disease,
or treatment in
the preceding
month with
glucocorticoids
Patients
5
previously
exposed to
TNF-α
inhibitors

Interventions

Patients
previously
treated with an
anti-TNF
besides
etanercept

Randomized to
receive 25mg
etanercept
subcutaneously
2x/week for the
first 72 weeks,
then 50mg
etanercept in two
doses of 25mg
subcutaneously
1x/week or
placebo

131

Randomized to
receive 25mg
etanercept or
placebo
subcutaneously
2x/week for 12
weeks
Randomized to
receive 50mg
etancercept
1x/week or
placebo
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methotrexate and sulfasalazine, while hydroxychloroquine was only allowed in Braun and Davis’
experiments. Corticosteroids begun two weeks proceeding to enrollment were acceptable in both
Braun and Davis’ studies.
In the study by Barkham et al, all 40 participants remained throughout the 12 weeks. No
statistical significance was found with overall AS-WIS scores (p=0.160); however, there was
improvement of scores with a 95% CI with a mean decrease of 2.75 in the etanercept group
compared to a decrease of 0.68 in placebo (table 2).7 Table 3 shows risk of job loss, where there
was a greater decrease in the risk of job loss for the etanercept group of 55% contrasted to the
placebo group who had only 35% decrease.7 The relative risk reduction (RRR) was calculated to
be 57.1% and absolute risk reduction (ARR) was 20%. Numbers needed to treat (NNT) was
calculated as 5, meaning 5 people need to be treated with etanercept in order to prevent one
person from work instability with AS.
Table 2: Changes in AS-WIS scores in those who received etanercept verse placebo
Treatment Group

Mean AS-WIS decrease

Etanercept

-2.75

Placebo

-0.68

Table 3: Risk of job loss
CER

EER

RRR

ARR

NNT

p-value

35%

55%

57.1%

20%

5

0.160

The study conducted by Braun et al was based on modified intention to treat where the
population includes patients who received at least one dose of etanercept or placebo. There were
356 participants who made up this population, and 321 completed the study (90%). At the
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beginning of the study, a large number of patients reported issues in the 5 aspects of the EQ-5D
scale: 79.8% reported problems with mobility, 89.9% with usual activities, 64.6% admitted to
anxiety/depression, 57% had problems with self care, and 99.2 reported pain or discomfort.

Statistically significant improvements (p<0.01) in all the EQ-5D categories were reported. After
12 weeks of treatment, 66% of etanercept patients had clinical benefit with improvement
compared to 50% of those with placebo as shown in table 4.8 The relative benefit increase (RBI)
was calculated to be 32% and absolute benefit increase (ABI) was 16%. NNT was calculated as
2, meaning 2 people need to be treated with 50mg etanercept once a week for 12 weeks in order
to improve 1 person’s quality of life compared to control. Statistically significant improvements
in the etanercept group were also seen with the BASFI from weeks 2-12 (table 5). At week 2, the
BASFI score decreased by 15 (p<0.05), week 4 by about 22 (p<0.001), week 8 about 25
(p<0.0001), and by week 12 the score decreased by approximately 27 (p<0.0001). No
statistically significant difference in the BASFI was seen with the placebo group: week 2 score
decreased about 7 and weeks 4-12 had a decrease of roughly 10.8
Table 4: Benefit of etanercept on improvement in EQ-5D
CER

EER

RBI

ABI

NNT

p-value

50%

66%

32%

16%

2

P<0.01

Table 5: Improvement in BASFI scores in etanercept group compared to placebo
Group

Week 2

Week 4

Week 8

Week 12

Etanercept

-15 (p<0.05)

-22 (p<0.001)

-25 (p<0.0001)

-27 (p<0.0001)

Placebo

-7

-10

-10

-10
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The study by Davis et al was an open label extension (OLE) of 168 weeks from a 24-

week experiment. There were 277 participants in the original study and 257 continued with the
OLE. Of these 257 participants, 129 received placebo and 128 received 50mg etanercept once a
week. Only 126 of these patients went on to complete the entire course of the experiment,
accounting for a 49% loss. The majority of losses were due to patient refusal, followed by
adverse effects, lack of efficacy, lost to follow-up, protocol violation, protocol requirement, and
lastly physician decision. Etanercept 50mg once per week was given to everyone for the 168
weeks of the OLE. Treatment with etanercept over 192 weeks was overall found to be safe.
Results were compared to the placebo group from the original RCT (table 6). The most common
adverse event was injection site reactions (ISR), and from the original 257 enrolled in the OLE,
57 (22.2%) reported an ISR. Of the 139 who received placebo in the RCT, 13 (9.4%) reported an
ISR.9 The relative risk increase (RRI) calculated was 139% and absolute risk increase (ARI) was
12.8%. Numbers needed to harm (NNH) was 8 meaning for every 8 people treated with
etanercept for 192 weeks, 1 person will be harmed with an ISR compared to control. Table 7
shows other adverse events of long-term etanercept treatment. Serious adverse events were only
reported from 33 participants (12.8%) with depression being the most common (1.2%).
Infections were also common in those treated with etanercept and developed in 187 (72.8%)
participants compared to 43 (30.9%) with placebo. The most common infections were upper
respiratory infections (45%) and sinusitis (16%). No deaths were reported from this study.9
Table 6: Harms from injection site reactions of those treated with 192 weeks etanercept
compared to 24 weeks placebo
CER

EER

RRI

ARI

NNH

9.4%

22.2%

139%

12.8%

8
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Table 7: Adverse events of long-term etanercept treatment compared to placebo
ISR
Infections
Serious
Depression
Death
Adverse
Events
Etanercept
57
187 (72.8)
33 (12.8%)
3 (1.2%)
0
(22.2%)
URI: 45%
Sinusitis: 16%
Placebo
13
43 (30.9%)
4 (2.9%)
Not
0
(9.4%)
Reported

DISCUSSION
This systematic review investigated the three RCTs for the safety and effectiveness of
etanercept as a treatment for AS. The studies by Braun et al and Davis et al demonstrated this
drug as a safe and effective treatment. Statistical significance was not reached in the study
conducted by Barkham et al; however, a relatively beneficial NNT of 5 still allows for some
efficacy.
Ankylosing spondylitis is a progressive disease with no current cure that can eventually
develop into immobility, so treatment to improve the lives of these patients is important.
Etanercept has been established to be a safe way to improve the quality of life and daily
functioning of those with AS. This drug has also been FDA approved for the treatment of
moderate to severe rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and
moderate to severe chronic plaque psoriasis.11 Although etanercept is an expensive drug,
insurance companies work with the patient to cover most if not all of the cost. There is currently
no generic available in the U.S. An ENBREL supportTM Card is also available to provide
assistance for eligible patients in need.11,12 Contraindications to treatment include a previous
hypersensitivity reaction to the drug or any part of its formulation and any individual with sepsis.
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It is also important not to administer live vaccines while undergoing treatment.11 Boxed warnings
for infections and malignancy are currently in place due to adverse events that have been seen in
those using etanercept. Severe infections including tuberculosis, invasive fungal, bacterial, viral,
and opportunistic infections have been noted, and lymphoma and other malignancies have been
seen in children.11
There were various limitations among the studies presented in this review. A small
sample size of 40 participants in the Barkham et al study may not have been sufficient enough
for a proper representation of the AS population. The Davis et al study was carried out for an
exceedingly long period of time, which may be a major contribution to the 51% participant loss
by the end of the 192 weeks. For all three studies, results may have been impacted by a variation
in occupations, daily activities, and lifestyles of each participant.
CONCLUSION
Etanercept is a safe treatment for AS and effective for improving quality of life and
physical functioning as revealed by this review. Effectiveness for work instability was seen, but
not enough to prove statistical significance. Future studies on work instability should be
performed with participants who have the same or similar occupation. Another direction for
future research should be aimed at a way to reduce adverse events associated with etanercept
treatment. Anti-TNF α therapy is becoming more widely used among the AS population. It
would be beneficial so determine the differences in outcomes between etanercept and other
commonly used Anti-TNF α drugs such as infliximab, adalimumab, and golimumab. Continuing
research on treatment for AS should provide those with the disease an opportunity to live a less
painful and debilitating life.
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